Castle Biosciences Inc (CSTL) FinancialsCSTLCastle Biosciences Inc

Evaluating the bottom line, Castle Biosciences, Inc. maintains a gross margin of 74.94%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.96%, while the net margin is -1.99%. These profitability ratios, combined with a Return on Equity (ROE) of -4.20%, provide a clear picture of how effectively CSTL converts its operational activities into shareholder value.

In the context of the broader market, CSTL competes directly with industry leaders such as CBLL and PRCT. With a market capitalization of $1.00B, it holds a significant position in the sector. When comparing efficiency, CSTL's gross margin of 74.94% stands against CBLL's 92.32% and PRCT's 66.01%. Such benchmarking helps identify whether Castle Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Castle Biosciences has shown strong revenue growth, with Q2 2026 revenue at $103.5 million, up 20% from the previous year, and gross margins consistently above 70%. However, the company has faced net losses in recent quarters, including a net loss of $2.1 million in Q2 2026.